INNOTEST® PHOSPHO-TAU (181P)

Single-analyte assays using Elisa technology 

The INNOTEST PHOSPHO-TAU(181P) is a solid-phase enzyme immunoassay for the quantitative determination of phosphorylated Tau (Phospho-Tau(181P)) in human cerebrospinal fluid (CSF).

The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression.1-5

The discrimination of AD from non-AD types of dementia such as dementia with Lewy Bodies may be further improved using the quantification of CSF-phospho-Tau(181). 6-7 

    Contact sales for information
    For research use only
    INNOTEST® PHOSPHO-TAU (181P)

    Product number 81581

    96 Tests
    Please contact your local Fujirebio representative for the availability of this product in your country.

    Click here to navigate

    • Contact sales for information
    • Details
    • Conditions of sale
    • Citations
    • Documentation
    • Insights
    • Product inquiry
    • Related products

    • Details

      Advantages of our assays

      • Simple colorimetric immunoassays that are easily automated on microplate-processor
      • Supported by many peer-reviewed scientific publications
      • Less than 300 μL of CSF necessary for determination of complete biomarker profile
      • Assay range consistent with biological range of values

        
      Clinical background

      Alzheimer’s disease (AD) is the most common form of dementia and is histologically characterized by the accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles throughout the brain. The major constituents of amyloid plaques are the β-amyloid peptides consisting of 40 and 42 amino acids, which are derived from the amyloid precursor protein. Neurofibrillary tangles are made up of paired helical filaments consisting of hyperphosphorylated tau protein (phospho-tau). Tau protein, present in the brain in 6 different isoforms, is an intracellular protein that is released upon neuronal death.

      A license regarding amyloid beta antibodies contained in this product under patents US 570349 and EP 0683234 has been obtained from Takeda Pharmaceutical Company Limited. Furthermore, a license for the use of amyloid beta monoclonal antibodies contained in this product under patents US 5,593,846A, US 5,766,846A, US 5,837,672A, US 6,284,221B1, US 6,610,493B1, US 5,441,870A, US 5,721,130A, US 5,605,811A and US 6,114,133A has been obtained from Eli Lilly and Company.

    • Conditions of sale

      To read the end user conditions of sale for this product please visit our Resource center.

    • Citations

    • Insights

    • Product inquiry

      CAPTCHA

      The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

      For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

      If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.

    Veuillez confirmer que vous êtes un professionnel de la santé

    Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

    Choose your country or region

    Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
    The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.